MPM Capital, a Cambridge, MA – and Brisbane, CA-based life-sciences venture capital firm investing in early-stage therapeutics companies, closed its seventh venture fund, at $400m.
With BioVentures 2018, MPM will continue to create and invest in innovative companies developing breakthrough therapies to treat severe unmet medical needs. The fund will focus on disruptive scientific developments across multiple therapeutic areas including oncology, immunology and neuroscience as well as emerging modalities of cell, gene and nucleic acid therapies.
Led by Ansbert Gadicke, M.D., co-founder and Managing Director, and Luke Evnin, Ph.D., co-founder and Managing Director, MPM invests across three vehicles with a total of over $1 billion in capital:
– BV2018, a venture capital fund;
– an oncology-only crossover fund (both private and public equities); and
– another oncology-focused investment initiative with Dana-Farber Cancer Institute.
At the core of its company-building strategy is a team of fifteen Executive Partners working in close collaboration with the investment team to jointly harness scientific creativity, entrepreneurship, and financial and business insights. The Executive Partner team includes senior biopharma leaders with decades of experience in drug discovery, clinical development and commercialization.
MPM’s team is involved in all aspects of company building, from identifying and evaluating new opportunities to creating companies and assuming senior leadership roles across the portfolio.
Recent examples of companies founded and led by MPM Executive Partners include Harpoon Therapeutics and TCR2 Therapeutics, both of which recently completed IPOs, and Mitobridge and Potenza Therapeutics, both of which were recently acquired.
Since its first fund in 1997, MPM has raised $3.9 billion of capital.